Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
21.99
+1.23 (5.92%)
At close: Mar 9, 2026, 4:00 PM EDT
20.99
-1.00 (-4.55%)
After-hours: Mar 9, 2026, 5:04 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
76
Market Cap
683.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 14 days ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
- 24 days ago - Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - Business Wire
- 4 weeks ago - Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Business Wire
- 7 weeks ago - Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
- 7 weeks ago - Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Business Wire
- 3 months ago - Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Business Wire
- 3 months ago - Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 - Seeking Alpha
- 4 months ago - Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire